Orphazyme sells entire business to US biotech company
Embattled biotech company Orphazyme has found a buyer in the form of a US-based biotech firm. If and when the deal is completed, the Danish company will close, and the majority of the remaining 20 employees will be transferred to the new owner.
by christian bundgaard, translated by catherine brett
Orphazyme has found a buyer after months of speculation.
The listed company, which has been going through a restructuring process, announced the planned acquisition in a stock exchange notification.
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”